<SEC-DOCUMENT>0001104659-21-123668.txt : 20211006
<SEC-HEADER>0001104659-21-123668.hdr.sgml : 20211006
<ACCEPTANCE-DATETIME>20211006164013
ACCESSION NUMBER:		0001104659-21-123668
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20211006
DATE AS OF CHANGE:		20211006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		211310158

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2129416d2_defa14a.htm
<DESCRIPTION>SCHEDULE 14A
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Proxy Statement Pursuant
to Section&nbsp;14(a) of the Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Filed by the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml; </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to Section&nbsp;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s)&nbsp;Filing Proxy Statement,
if Other Than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and 0-11.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title of each class of securities to which transaction applies: &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Aggregate number of securities to which transaction applies: &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule&nbsp;0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Proposed maximum aggregate value of transaction: &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Total fee paid: &nbsp;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2)&nbsp;and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form&nbsp;or Schedule and the date of its filing.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amount Previously Paid: &nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form, Schedule or Registration Statement No.: &nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Filing Party: &nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Date Filed:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2129416d2_defa14aimg01.jpg" ALT="" STYLE="height: 42px; width: 139px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021, Synthetic Biologics, Inc.
filed the following Current Report on Form&nbsp;8-K and issued the related press release, which is furnished as Exhibit&nbsp;99.1 to the
Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM <FONT ID="xdx_90D_edei--DocumentType_c20211006__20211006_zQZtxr5jffFd">8-K</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): <FONT ID="xdx_90B_edei--DocumentPeriodEndDate_c20211006__20211006_zPtk88pU1yBf">October 6, 2021</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="xdx_909_edei--EntityRegistrantName_c20211006__20211006_zOCO9TNXNsUh">SYNTHETIC BIOLOGICS, INC.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><FONT ID="xdx_904_edei--EntityIncorporationStateCountryCode_c20211006__20211006_zb6fapGEXcSf">Nevada</FONT></B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><FONT ID="xdx_905_edei--EntityFileNumber_c20211006__20211006_z2Yu8RfosX55">001-12584</FONT></B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><FONT ID="xdx_909_edei--EntityTaxIdentificationNumber_c20211006__20211006_zytghaQ35Sfl">13-3808303</FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&#160;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&#160;</TD>
    <TD STYLE="padding-right: 0.8pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="xdx_90F_edei--EntityAddressAddressLine1_c20211006__20211006_zHU6sRJlKoW6">9605 Medical Center Drive</FONT>, <FONT ID="xdx_909_edei--EntityAddressAddressLine2_c20211006__20211006_z1WoMffN15me">Suite 270</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="xdx_906_edei--EntityAddressCityOrTown_c20211006__20211006_zFALFy9cu9ml">Rockville</FONT>, <FONT ID="xdx_90E_edei--EntityAddressStateOrProvince_c20211006__20211006_zArTqLZxu5cc">Maryland</FONT> <FONT ID="xdx_90E_edei--EntityAddressPostalZipCode_c20211006__20211006_zXOtCSAAgXF">20850</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(<FONT ID="xdx_90E_edei--CityAreaCode_c20211006__20211006_zaUdtcZSv5L9">301</FONT>) <FONT ID="xdx_908_edei--LocalPhoneNumber_c20211006__20211006_zMTPgrgM9of6">417-4364</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Wingdings"><FONT ID="xdx_903_edei--WrittenCommunications_c20211006__20211006_zenPO7GNy6Ld">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Wingdings"><FONT ID="xdx_90D_edei--SolicitingMaterial_c20211006__20211006_z17ViP1OZ5n1">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Wingdings"><FONT ID="xdx_905_edei--PreCommencementTenderOffer_c20211006__20211006_zGecfaeC8mB2">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Wingdings"><FONT ID="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20211006__20211006_zspRajOGLT6l">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><FONT ID="xdx_90A_edei--Security12bTitle_c20211006__20211006_zXdqnDsAUw03">Common stock, par value $0.001 per share</FONT></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><FONT ID="xdx_90B_edei--TradingSymbol_c20211006__20211006_zSAZcUTpybD9">SYN</FONT></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><FONT ID="xdx_903_edei--SecurityExchangeName_c20211006__20211006_zNdvuurDa2ok">NYSE American</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings"><FONT ID="xdx_90B_edei--EntityEmergingGrowthCompany_c20211006__20211006_zxNTwKa73OEj">&#168;</FONT></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 6, 2021, Synthetic
Biologics, Inc. (the &#8220;Company&#8221;) reconvened its 2021 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At
that time, there were not present or represented by proxy a sufficient number of shares of the Company&#8217;s common stock to constitute
a quorum. <FONT STYLE="background-color: white">As a result, the Company determined to adjourn the Annual Meeting for a second time, which
will reconvene at 9:30 a.m.&#160;Eastern Time on Thursday, October 14, 2021 </FONT>at the Company&#8217;s corporate headquarters located
at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The record date for the
Annual Meeting remains&#160;August 9, 2021. Stockholders of the Company who have previously submitted their proxy or otherwise voted and
who do not want to change their vote do not need to take any action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No changes have been
made in the proposals to be voted on by stockholders at the Annual Meeting. The Company strongly encourages all of its stockholders to
read the Company&#8217;s definitive proxy statement on Schedule 14A, filed with the&#160;Securities and Exchange Commission&#160;(the
 &#8220;SEC&#8221;) on&#160;August 16, 2021 (the &#8220;Proxy Statement&#8221;) and other proxy materials relating to the Annual Meeting,
which are available free of charge on the&#160;SEC&#8217;s&#160;website at&#160;<I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current adjournment, the Company will
continue to solicit votes from its stockholders with respect to the proposals set forth in the Proxy Statement. As set forth in the Proxy
Statement, the Company has engaged a proxy solicitor, D.F. King &amp; Co., Inc. to assist management with obtaining adequate votes to
achieve the required quorum of at least a majority of the outstanding shares of the Company&#8217;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 6, 2021, the
Company issued a press release to announce the second adjournment, which is furnished as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K.
The information in the press release furnished as Exhibit&#160;99.1 hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18
of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section,
or incorporated by reference into any of the Company&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in any such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&#160;&#160;</FONT></TD>
    <TD STYLE="width: 99%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; width: 89%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&#160;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press release of Synthetic Biologics, Inc., dated October 6, 2021&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&#160;</TD>
    <TD STYLE="padding-right: 0.8pt">&#160;</TD>
    <TD STYLE="padding-right: 0.8pt">&#160;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">104</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&#160;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the XBRL document)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;&#160;</B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: October 6, 2021</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&#160;</TD>
    <TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 3%">&#160;</TD>
    <TD STYLE="width: 43%">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">and Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="tm2129416d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces Second Adjournment
of Annual Meeting of Shareholders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Due to Lack of Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The Company Encourages All Shareholders of Record
Who Have Not Yet Voted to Do So by October 13, 2021; Shareholders of Record May Vote Their Shares by Calling D.F. King &amp; Co., Inc.
Toll-free at 1-800-859-8509</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext"><B>Rockville,
MD, October 6, 2021 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a
diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (&ldquo;GI&rdquo;)
diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today announced the Company&rsquo;s reconvened annual meeting of
shareholders, on October 6, 2021, at 9:30 a.m. ET, was adjourned for a second time without any business being conducted due to lack of
the required quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A quorum consists of a majority of the shares
entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by proxy at this meeting. Approximately
48.6% of the shares of the Company&rsquo;s common stock outstanding as of the record date were properly voted at the time of the annual
meeting. The annual meeting of shareholders therefore had no quorum and the meeting was adjourned for a second time and will reconvene
at 9:30 a.m. ET on Thursday, October 14, 2021 at the Company&rsquo;s corporate headquarters 9605 Medical Center Drive, Suite 270, Rockville,
MD 20850 to allow additional time for the Company&rsquo;s shareholders to vote on the proposals set forth in the Company&rsquo;s definitive
proxy statement filed with the United States Securities and Exchange Commission (the &ldquo;S.E.C.&rdquo;) on August 16, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current adjournment, the Company will
continue to solicit votes from its shareholders with respect to the proposals set forth in the Company&rsquo;s proxy statement. As set
forth in the proxy statement, the Company has engaged a proxy solicitor, D.F. King &amp; Co., Inc. to assist management with obtaining
adequate votes to achieve the required quorum of at least a majority of the outstanding shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">The
Company encourages all shareholders of record, as of the record date August 9, 2021, who have not yet voted, to do so by October 13,
2021 at 11:59 p.m. ET. Shareholders who have any questions or require any assistance with completing a proxy or voting instruction form
or who do not have the required materials, may contact D.F. King &amp; Co., Inc. using the following contact information 48 Wall Street,
22<SUP>nd</SUP> Floor, New York, NY 10005, Telephone: Toll Free: 1-800-859-8509 and Outside North America: +1-212-269-5550. Email: </FONT><U>synthetic@dfking.com</U><FONT STYLE="color: windowtext">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade
certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage,
(b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance
(AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020,
a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat
both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions. These forward-looking statements
are based on management&rsquo;s expectations and assumptions as of the date of this press release and are subject to a number of risks
and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to
differ materially from current expectations include, among others, the ability of Synthetic Biologics to receive the necessary regulatory
approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo; clinical trials, and
those conducted by investigators, for SYN-004 and SYN-020 to be commenced or completed on time, to provide topline data when anticipated
or to achieve desired results and benefits, especially in light of COVID-19, a failure of Synthetic Biologics&rsquo; clinical trials to
continue enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell
its products, Synthetic Biologics&rsquo; inability to maintain its material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics&rsquo; Annual Report
on Form 10-K for the year ended December 31, 2020 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q
and 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except
as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
<U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2129416d2_defa14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2129416d2_defa14aimg01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *@"+ P$1  (1 0,1 ?_$ ,@   $#!0$!
M      @ !PD#! 4&"@$" 0  !@,! 0               P0%!@@"!PD!"A
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M:5(A Y911*%())$%04# 1$ ;[=:)7;]W5?RHTZAM!M=0?D'%ME,8!U)YB,Q
MC" @;B8F%K'>GC.2QOE61NK%+WO'>5'(VJK6-D8%XM5Y*-TGLA&@X2#1 X'5
M\9(IN2B*@& >0@#'\U6U4WI76D_K=AMLZ=J=2+[+B,RDY5<%$)@#'K/;9?\
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M!E ([ZD%(-^;I2F./&VE-C-65[2VLYC9G62EKF&&U+DW4WY@F&5*E*@3%,2
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?]/R_@]Z&'A\7#^U;8/\ @[?Z?]7T<(/^G:0?LM__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2129416d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2129416d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 60# 2(  A$! Q$!_\0
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M_:K,=;6X)*X_V3U7_/%>Z>#_ !SIOC2T,EH_EW*#][:R'YT]_<>XK]GR#B_
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MO+NOZZ$M%%%?='S04444 %%%% ''_&#X@)\*?A=XG\7/!]I_L>PDND@)P)'
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MGD"/S1L5L[<G'WL=>U?J)^V)^T->_ /X#Z*N@RK!XHUZ..RL)B ?LRB(&68
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MO;22M% SQG#;&<!AGW''T)K.EC^; O&2CLF[>E_\C;$9,H9Q'*J<_BE!7?\
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MX[V>387+8O5WG+RNVXKYIW^X6BBBOK3XT**** "BBB@ HHHH **** "BBB@
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@S$XN7-B*DIO^\V_S'T445L<@4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
